Given that I am supposed to present the 'Top Ten' partnering list, and then chair a panel with the neuroscience heads from Merck, JNJ, and BTG, I'd better show up at Windhover.
But it's unlikely I'll have much insight into who is talking to whom--those assignations tend to happen behind closed doors. And if by chance someone I know from a BP were to come up to talk to me about the RD/CX717 topic--frankly, most big companies would not appreciate having their interest broadcast on an internet discussion board, and I wouldn't do or say anything that might get in the way of the partnering process. I haven't survived in this business for 13 years by being indiscreet, and I am very clear on what the bottomline priority is here.
NeuroInvestment